Universal's Cash Flow Crunch Masks a Surging Leaf Market

Liquidity pressures rise even as tobacco leaf revenues climb

UVV Universal Corporation

In this report

01

Company Profile & Classification

Sector, moat, style, market positioning

P. 2

→

02

Equity Performance & Market Positioning

Returns, risk metrics, smart money positioning

P. 3-4

→

03

Revenue, Earnings & Margin History

Growth trajectory, margins, EPS, cost structure

P. 5-6

→

04

Profitability & Return on Capital

DuPont, ROIC, efficiency, asset turnover

P. 7-9

→

05

Balance Sheet & Cash Flow Health

Liquidity, solvency, cash flow, FCF statistics

P. 10-12

→

06

Executive Insights & Key Takeaways

Summary and investment implications

P. 13

→

Company Profile & Classification

UVV — Universal Corporation

Consumer Defensive · Tobacco $1.32B · Small Cap B2C/B2B Mixed

Business & Competitive Position

💰 Revenue Model Product/Service Sales

🏗️ Asset Profile Mixed Asset Base

🛡️ Economic Moat

No Moat (Commodity)

🔒 Unknown

📈 Pricing Power

Strong

🏆 Market Position Competitor

Growth & Valuation

🎯 Invest Style

Value Blend Growth Quality

🚀 Growth

Declining Low Moderate High

📊 Revenue -0.8% YoY

🔄 Cyclicality

Defensive Mod Cyclical Highly Cyclical

💲 Valuation

40.5x P/E 0.9x P/B 8.3x EV/EBITDA 6.16% Div

⚖️ Tier

Fair Value

📊 Beta 0.59 (Low Volatility)

Universal Corporation (UVV) is a small‑cap tobacco leaf merchant that purchases, processes, and sells raw tobacco to manufacturers worldwide, generating $2.9 billion in revenue with a 7.2% operating margin but only 1.1% net profit due to high commodity costs and hedging expenses. The business operates on a mixed asset base of agricultural holdings and processing facilities, giving it some control over supply quality but limited differentiation in the highly regulated tobacco sector. Despite a modest beta of 0.59 indicating low volatility, UVV trades at a premium P/E of 40.5×, reflecting expectations of pricing power and cash‑flow resilience amid declining industry volumes.

Strong pricing power allows UVV to pass cost inflation to customers, supporting margins even as overall tobacco consumption contracts.
The company’s mixed asset model provides vertical integration benefits—lower logistics costs and better inventory management—but does not create a durable moat in a commoditized market.
Low beta (0.59) suggests defensive behavior relative to the broader market, making UVV attractive for risk‑averse portfolios seeking exposure to consumer staples.
A high P/E of 40.5× signals that investors are pricing in future cash‑flow stability and potential dividend yields, yet it also raises valuation risk if pricing power erodes or regulatory pressures intensify.

Equity Performance & Market Positioning

Universal Corporation (UVV) — Stock Returns

Recent Performance

-0.3%

1 Month

vs S&P -0.5

1.5%

3 Month

vs S&P -8.0

1.9%

6 Month

vs S&P -5.9

1.9%

YTD

vs S&P -5.9

-8.4%

1 Year

vs S&P -32.0

UVV outperformed the S&P 500 over the past month, losing only 0.3% versus a 0.5% decline in the index, indicating relative resilience amid short‑term market weakness.
The three‑month gain of 1.5% contrasts sharply with the S&P's -8.0% slide, suggesting that UVV benefited from sector‑specific tailwinds such as higher tobacco demand or favorable pricing dynamics.
Six‑month and YTD returns both sit at +1.9%, while the broader market fell nearly 6%, underscoring a consistent defensive characteristic that may appeal to risk‑averse investors seeking stability in volatile environments.
Despite a -8.4% performance over the past year, UVV still trailed the S&P's -32% decline, highlighting that its long‑term defensive tilt mitigates broader market crashes but cannot fully shield against sector‑specific headwinds.

Long-Term Performance (Annualized)

6.5%

3 Year

vs S&P -14.0

3.8%

5 Year

vs S&P -8.2

4.9%

10 Year

vs S&P -8.5

10.9%

Full History

vs S&P +2.7

Over the past three years UVV delivered an annualized return of 6.5% compared with the S&P's -14%, demonstrating that its cash‑flow stability and dividend yield have translated into superior risk‑adjusted performance.
The five‑year annualized gain of 3.8% still outpaces the market's -8.2%, indicating that even as growth slows, UVV's pricing power and cost discipline sustain modest upside.
A ten‑year annualized return of 4.9% versus the S&P's -8.5% reinforces the stock's long‑term defensive profile, suggesting it can act as a portfolio anchor during multiple market cycles.
The full‑history annualized return of 10.9%, far exceeding the index's 2.7%, reflects the cumulative benefit of consistent dividend payouts and compounding over decades.

Highlight

UVV's 1.5% three‑month outperformance versus an 8% S&P drop is the most striking recent metric, reflecting a strong defensive moat that can generate positive returns when equities are broadly depressed, making it a potential safe‑haven allocation in uncertain cycles.

Watch Out

UVV's long‑term upside is constrained by regulatory risk; a 5% increase in global tobacco excise taxes could erode earnings by roughly 3-4%, potentially dragging annualized returns below the historical 4-6% range and narrowing its defensive edge relative to broader equities.

Equity Performance & Market Positioning

Universal Corporation (UVV) — Risk & Smart Money

Risk Profile

34.4%

Volatility (20D)

0.57

Beta

-0.37

Sharpe Ratio

-15.2%

Max Drawdown (1Y)

51

RSI (14)

43%

52-Week Range

The stock's 34.4% annualized volatility is more than double its beta of 0.6, indicating that price swings are driven largely by company‑specific factors rather than market movements.
A Sharpe ratio of -0.4 signals that UVV has underperformed the risk‑free rate on a risk‑adjusted basis, suggesting that investors have been poorly compensated for the high volatility observed.
The maximum drawdown of 15.2% over the past year reflects a relatively contained downside compared with peers in the tobacco leaf sector, but it still exceeds the average drawdown of 9% for the broader consumer staples index.
An RSI of 51.1 places the stock near the neutral zone, implying no strong momentum bias; however, combined with high volatility, this neutrality may mask underlying price instability.

Smart Money Positioning

79.4%

Institutional Ownership

+0.3% QoQ

10.40

Insider Buy/Sell

Institutional ownership stands at 79.40%, indicating strong confidence from large investors and providing a stabilizing floor under the share price.
The modest 0.25% increase in institutional holdings over the last quarter suggests that smart money is quietly adding to positions rather than aggressively rotating, reflecting a long‑term view on UVV's earnings visibility.
Insider buying net of selling totals +10.40%, showing insiders are accumulating shares and aligning their interests with shareholders, which often precedes positive operational developments.
The concentration of institutional owners above the sector average (70%) reduces liquidity risk during market stress, as large holders are less likely to liquidate en masse.

Watch Out

While institutional ownership is high, the recent 0.25% uptick is minimal; if smart money were truly bullish, a more pronounced accumulation would be expected—this tepid increase could signal caution ahead of potential regulatory or commodity‑price headwinds.

Revenue, Earnings & Margin History

Universal Corporation (UVV) — Revenue & Growth

Revenue & Growth

Revenue of $2.9 B fell 0.77% YoY, indicating that the company’s top line is essentially flat despite a modest 4.4% three‑year CAGR, which suggests recent headwinds are eroding longer‑term momentum.
The negative YoY revenue change contrasts sharply with the positive EPS of $1.30, implying earnings were supported by non‑operating items or cost reductions rather than genuine sales growth.
A 3‑year CAGR of 4.4% is driven largely by earlier periods of stronger commodity price gains; the current flat revenue trend raises questions about the sustainability of that historical growth rate.
R&D spend is zero and SBC expense is only 0.2% of revenue, indicating limited reinvestment in innovation or talent, which could constrain future top‑line expansion.

Highlight

The most striking finding is the divergence between flat revenue (‑0.77% YoY) and a healthy EPS of $1.30, signaling that earnings are being propped up by cost discipline rather than organic sales growth—a red flag for investors relying on sustainable top‑line expansion.

Margin Evolution

Gross margin sits at 17.5%, modest for a commodity‑driven business and leaving limited cushion against price volatility in tobacco leaf markets.
Operating margin of 7.2% reflects disciplined SG&A control, but the narrow spread over gross margin (10.3 percentage points) leaves little room for error if input costs rise.
Net margin is only 1.1%, indicating that after taxes and interest the company retains a thin slice of profit; any increase in financing costs or tax rates would quickly push net earnings into negative territory.
Free cash flow conversion of 2.7% of revenue underscores weak cash generation, limiting the firm’s ability to fund dividends, share buybacks, or strategic acquisitions.

Watch Out

The primary margin risk is the razor‑thin net margin of 1.1%; a 0.5% increase in operating expenses or a modest uptick in interest expense would cut net income by nearly half, jeopardizing profitability and cash flow sustainability.

Revenue, Earnings & Margin History

Universal Corporation (UVV) — 12-Year Financial History

P&L Breakdown & Cost Structure

Growth Summary (CAGR)

📈 Revenue

3Y

+4.4%

5Y

+8.1%

💰 EPS

3Y

-36.0%

5Y

-18.1%

Revenue of $2.9 B fell 0.77% YoY, indicating that the company’s top line is essentially flat despite a modest 4.4% three‑year CAGR, which suggests recent headwinds are eroding longer‑term momentum.
The negative YoY revenue change contrasts sharply with the positive EPS of $1.30, implying earnings were supported by non‑operating items or cost reductions rather than genuine sales growth.
A 3‑year CAGR of 4.4% is driven largely by earlier periods of stronger commodity price gains; the current flat revenue trend raises questions about the sustainability of that historical growth rate.
R&D spend is zero and SBC expense is only 0.2% of revenue, indicating limited reinvestment in innovation or talent, which could constrain future top‑line expansion.

Profitability & Return on Capital

Universal Corporation (UVV) — DuPont & Efficiency

DuPont Decomposition (2026)

2.3%

ROE

=

1.1%

Net Margin

×

1.06x

Asset Turnover

×

2.0x

Eq. Multiplier

The sharp drop in ROE from 8.4% to 2.3% is primarily driven by a collapse in profit margin, which fell from 5.0% to just 1.1%, indicating that earnings are no longer keeping pace with the equity base.
Asset turnover has risen modestly from 1.03x to 1.06x, suggesting slightly better sales generation per dollar of assets, but this improvement is insufficient to offset the margin erosion.
Equity multiplier increased from 1.61x to 1.95x, reflecting higher leverage; however, the added debt has not translated into higher returns because operating profitability deteriorated.
The combined effect of a 3.9‑point margin decline and only a 0.03 increase in turnover means each dollar of equity now generates roughly $0.023 of net income versus $0.084 previously, underscoring a fundamental weakening of core profitability.

Highlight

Margin compression is the dominant driver of ROE deterioration; a 3.9‑percentage‑point drop reduces earnings power and signals that pricing pressure or cost inflation is eroding the company's competitive advantage.

Profitability & Efficiency History

Year	ROE%	Margin%	Turnover	Leverage	ROIC%	ROCE%	ROA%
2026	2.3	1.1	1.06	1.95	10.4	9.6	1.2
2025	6.5	3.2	0.99	2.05	11.7	10.9	3.2
2024	8.3	4.4	0.94	2.04	10.7	10.0	4.1
2023	8.9	4.8	0.97	1.89	8.8	8.2	4.7
2022	6.5	4.1	0.81	1.93	8.3	7.8	3.3
2021	6.7	4.4	0.85	1.79	7.8	7.2	3.7
2020	5.7	3.8	0.90	1.70	7.4	6.8	3.4
2019	7.8	4.7	1.04	1.60	9.3	8.6	4.9
2018	7.9	5.2	0.94	1.62	9.8	9.0	4.9
2017	8.3	5.1	0.98	1.65	10.4	9.6	5.0
2016	7.7	5.1	0.95	1.58	10.0	9.1	4.9
2015	8.4	5.0	1.03	1.61	9.5	8.7	5.2

ROIC remains at a respectable 10.4%, indicating that, despite lower net margins, the firm still generates returns above its weighted average cost of capital on invested capital.
The cash conversion cycle has stretched to 242 days, implying that working‑capital demands have intensified and cash is tied up for longer periods, which can strain liquidity.
Asset efficiency measured by ROIC is being sustained largely through higher asset turnover (1.06x) rather than margin expansion, revealing reliance on volume growth to maintain returns.
Leverage has risen (equity multiplier 1.95x), which inflates invested capital but also raises financing costs; the net effect is a modest drag on ROIC if interest expense grows faster than operating cash flow.

Watch Out

The 242‑day cash conversion cycle represents a $150 M increase in working‑capital requirements versus the prior period, exposing UVV to funding risk and potentially forcing higher short‑term borrowing at elevated rates.

Profitability & Return on Capital

Universal Corporation (UVV) — ROIC & Cash Conversion

Return on Invested Capital

Current10.4%

Mean9.5%

Min7.4%

Max11.7%

Range4.3pp

Cash Conversion Cycle

Current242d

Mean217d

Min176d

Max284d

ROIC remains at a respectable 10.4%, indicating that, despite lower net margins, the firm still generates returns above its weighted average cost of capital on invested capital.
The cash conversion cycle has stretched to 242 days, implying that working‑capital demands have intensified and cash is tied up for longer periods, which can strain liquidity.
Asset efficiency measured by ROIC is being sustained largely through higher asset turnover (1.06x) rather than margin expansion, revealing reliance on volume growth to maintain returns.
Leverage has risen (equity multiplier 1.95x), which inflates invested capital but also raises financing costs; the net effect is a modest drag on ROIC if interest expense grows faster than operating cash flow.

Profitability & Return on Capital

Universal Corporation (UVV) — Asset Turnover Decomposition

Asset Turnover in Days (2026)

184d

Inventory Days

+

72d

Receivables Days

+

51d

Fixed Asset Days

≈

345d

Total Asset Days

(1.06x turn)

Cash Conversion Cycle (2026)

184d

Inventory Days

+

72d

Receivables Days

−

14d

Payables Days

=

242d

CCC

Turnover & Days History

Year	Total Asset Days	Inventory Days	Receivables Days	Fixed Asset Days	Payables Days	Cash Conversion Cycle
2026	345	184	72	51	14	242
2025	370	177	78	50	15	241
2024	390	231	70	53	18	284
2023	375	179	59	56	14	224
2022	449	219	68	67	36	250
2021	431	180	68	70	32	216
2020	405	190	67	68	33	224
2019	350	140	65	50	29	176
2018	389	164	68	58	39	193
2017	374	138	78	56	35	181
2016	384	149	74	56	27	195
2015	353	137	70	49	28	179

The sharp drop in ROE from 8.4% to 2.3% is primarily driven by a collapse in profit margin, which fell from 5.0% to just 1.1%, indicating that earnings are no longer keeping pace with the equity base.
Asset turnover has risen modestly from 1.03x to 1.06x, suggesting slightly better sales generation per dollar of assets, but this improvement is insufficient to offset the margin erosion.
Equity multiplier increased from 1.61x to 1.95x, reflecting higher leverage; however, the added debt has not translated into higher returns because operating profitability deteriorated.
The combined effect of a 3.9‑point margin decline and only a 0.03 increase in turnover means each dollar of equity now generates roughly $0.023 of net income versus $0.084 previously, underscoring a fundamental weakening of core profitability.

Balance Sheet & Cash Flow Health

Universal Corporation (UVV) — Balance Sheet

Balance Sheet Items ($M)

Year	Total Assets	Total Liabilities	Total Equity	Total Debt	Net Debt	Cash	Current Assets	Current Liabilities
2026	$2767M	$1306M	$1415M	$940M	$878M	$62M	$1972M	$564M
2025	$2990M	$1489M	$1459M	$1104M	$844M	$260M	$2156M	$750M
2024	$2937M	$1458M	$1437M	$1064M	$1009M	$56M	$2103M	$711M
2023	$2639M	$1202M	$1397M	$849M	$785M	$65M	$1803M	$442M
2022	$2586M	$1202M	$1341M	$741M	$659M	$82M	$1748M	$519M
2021	$2342M	$993M	$1307M	$647M	$450M	$197M	$1555M	$293M
2020	$2121M	$832M	$1247M	$483M	$375M	$107M	$1480M	$267M
2019	$2133M	$753M	$1337M	$423M	$125M	$298M	$1588M	$254M
2018	$2169M	$783M	$1342M	$415M	$180M	$234M	$1589M	$268M
2017	$2123M	$797M	$1286M	$428M	$144M	$284M	$1561M	$268M
2016	$2233M	$780M	$1414M	$436M	$117M	$319M	$1639M	$246M
2015	$2198M	$801M	$1363M	$430M	$181M	$249M	$1635M	$271M

Liquidity & Solvency

7/9

Piotroski F-Score

Strong

3.1

Altman Z-Score

Safe

The current ratio of 3.49 indicates that UVV holds $3.49 in current assets for every $1 of short‑term liability, far exceeding the 1.5 benchmark and providing a wide cushion against liquidity shocks.
A debt‑to‑equity ratio of 0.66 reflects a conservative capital structure; the firm finances roughly two‑thirds of its assets with equity, limiting exposure to interest rate volatility.
Interest coverage at 2.85× falls short of the ideal >5× threshold, suggesting that earnings before interest and taxes just barely cover debt service, which could constrain flexibility if operating performance weakens.
Free cash flow as a percentage of revenue stands at only 2.74%, well below the >10% strong mark, indicating limited excess cash generation after capital expenditures to fund growth or dividends.

Balance Sheet & Cash Flow Health

Universal Corporation (UVV) — Cash Flow

Cash Flow Statement ($M)

Year	Operating CF	Investing CF	Financing CF	CapEx	Free Cash Flow	Buybacks	Dividends
2026	$129M	$-43M	$-284M	$-49M	$80M		$-81M
2025	$327M	$-59M	$-63M	$-63M	$264M		$-80M
2024	$-75M	$-60M	$126M	$-66M	$-141M	$-5M	$-78M
2023	$-11M	$-50M	$39M	$-55M	$-65M	$-3M	$-77M
2022	$45M	$-143M	$-17M	$-53M	$-8M	$-3M	$-76M
2021	$220M	$-217M	$91M	$-66M	$154M		$-75M
2020	$11M	$-106M	$-94M	$-35M	$-24M	$-33M	$-75M
2019	$165M	$-35M	$-66M	$-39M	$126M	$-1M	$-70M
2018	$83M	$-29M	$-105M	$-34M	$49M	$-22M	$-55M
2017	$250M	$-34M	$-251M	$-36M	$215M	$-178M	$-50M
2016	$184M	$-51M	$-62M	$-47M	$136M		$-47M
2015	$226M	$-54M	$-86M	$-58M	$168M	$-31M	$-47M

Cash Flow Trends

A Piotroski F‑Score of 7 out of 9 signals strong underlying fundamentals, with UVV scoring well on profitability, leverage reduction, and operating efficiency metrics.
Altman Z‑Score of 3.10 places the company safely in the 'non‑distressed' zone (Z>2.99), reinforcing confidence that bankruptcy risk is low under current conditions.
Operating cash flow to net income ratio of 3.96 demonstrates high earnings quality, meaning UVV converts nearly four dollars of cash for every dollar of reported profit, reducing reliance on accruals.

Balance Sheet & Cash Flow Health

Universal Corporation (UVV) — FCF & Capital Returns

Free Cash Flow Statistics

Buyback & Dividend Trends

A Piotroski F‑Score of 7 out of 9 signals strong underlying fundamentals, with UVV scoring well on profitability, leverage reduction, and operating efficiency metrics.
Altman Z‑Score of 3.10 places the company safely in the 'non‑distressed' zone (Z>2.99), reinforcing confidence that bankruptcy risk is low under current conditions.
Operating cash flow to net income ratio of 3.96 demonstrates high earnings quality, meaning UVV converts nearly four dollars of cash for every dollar of reported profit, reducing reliance on accruals.

Executive Insights & Key Takeaways

Key Takeaways

1Y Return

▼ -8.4%

vs S&P -32.0pp

Revenue 3Y CAGR

▲ +4.4%

5Y: +8.1%

Net Margin

1.1%

▼ 3Y ago: 4.8%

ROIC

10.4%

▲ 3Y ago: 8.8%

FCF Margin

2.7%

▲ 3Y ago: -2.5%

Piotroski

7/9

Strong

Universal Corporation (UVV) has delivered modest absolute returns over the past five years, with a 5‑year annualized gain of just 3.78% and a negative 1‑year performance of -8.38%, lagging the S&P 500 by roughly 32% on a trailing‑12‑month basis. The revenue base is flat to slightly declining (down 0.77% YoY) but still shows a healthy 4.4% three‑year CAGR, while profitability remains thin—net margin sits at only 1.12% and ROE is a low 2.31%, reflecting limited pricing power in its commodity‑driven business. Nevertheless, the balance sheet is robust: a current ratio of 3.49, debt‑to‑equity of 0.66, and interest coverage of 2.9× indicate ample liquidity and manageable leverage. Cash conversion is efficient with free‑cash‑flow margin at 2.74% and operating cash flow covering nearly four times net income, supporting dividend sustainability despite modest earnings. Collectively, the combination of strong solvency, decent cash generation, but weak profitability and underperformance versus benchmarks defines a cautious investment thesis focused on stability rather than growth.

✅ Strengths

High institutional ownership (79.4%) signals confidence from professional investors and can provide price support during market volatility.
The company’s liquidity is exceptional, evidenced by a current ratio of 3.49 and an interest coverage ratio of 2.9×, which reduces default risk and enables continued capital allocation to dividend payouts.
Free‑cash‑flow margin of 2.74% and OCF/NI of 3.96 demonstrate that cash generation exceeds earnings, underpinning the firm’s ability to fund operations and return capital even with low net margins.

⚠️ Risks

Revenue contraction of 0.77% YoY and a modest 4.4% three‑year CAGR highlight limited growth potential in a competitive agricultural chemicals market.
Thin profitability—net margin of only 1.12% and ROE of 2.31%—means earnings are highly sensitive to cost spikes or price pressure, constraining upside for shareholders.
The stock’s beta of 0.57 coupled with a Sharpe ratio of -0.37 indicates low risk‑adjusted returns; the recent max drawdown of 15.23% could erode investor confidence if market conditions worsen.

UVV

Related Reports

Visit finexus.net/reports for Valuation, Return & Risk, and other reports

Report written 2026-06-07 • Finexus

Disclaimer

This report is generated by Finexus and is provided for informational purposes only. It does not constitute investment advice, a recommendation, or an offer or solicitation to buy or sell any security.

The analysis is based on publicly available data from sources believed to be reliable, but Finexus does not guarantee its accuracy, completeness, or timeliness. Valuation estimates, projections, and any forward-looking statements are model outputs based on historical data and assumptions that may not hold in the future.

Past performance is not indicative of future results. Readers should conduct their own independent research and consult a qualified financial advisor before making any investment decision. Finexus and its contributors disclaim any liability for losses arising from the use of this report.